These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
340 related articles for article (PubMed ID: 16832956)
41. Investigational new drug applications; amendment to clinical hold regulations for products intended for life-threatening diseases and conditions. Food and Drug Administration, HHS. Final rule. Fed Regist; 2000 Jun; 65(106):34963-71. PubMed ID: 11010726 [TBL] [Abstract][Full Text] [Related]
42. Accelerated approval seen as triumph and roadblock for cancer drugs. Susman E J Natl Cancer Inst; 2004 Oct; 96(20):1495-6. PubMed ID: 15494596 [No Abstract] [Full Text] [Related]
43. New FDA breakthrough-drug category--implications for patients. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2014 Mar; 370(13):1252-8. PubMed ID: 24670173 [No Abstract] [Full Text] [Related]
44. An audience with Tatiana Prowell. Interviewed by Asher Mullard. Prowell T Nat Rev Drug Discov; 2014 Jun; 13(6):410-1. PubMed ID: 24875091 [No Abstract] [Full Text] [Related]
45. FDA treads delicate line between safety and speed. Oncology (Williston Park); 1999 Jan; 13(1):16. PubMed ID: 10027195 [No Abstract] [Full Text] [Related]
46. [Off-label use in oncology. The Italian choice]. Felicetti V; Gremigni U; Cifaldi L Recenti Prog Med; 2008 Dec; 99(12):612-5. PubMed ID: 19388222 [TBL] [Abstract][Full Text] [Related]
47. Cancer drug approval in the United States, Europe, and Japan. Milsted RA Adv Cancer Res; 2007; 96():371-91. PubMed ID: 17161686 [No Abstract] [Full Text] [Related]
48. Phase 0 clinical trials in oncology: a paradigm shift for early drug development? Takimoto CH Cancer Chemother Pharmacol; 2009 Mar; 63(4):703-9. PubMed ID: 18615251 [TBL] [Abstract][Full Text] [Related]
49. The Right to Try: An Overview of Efforts to Obtain Expedited Access to Unapproved Treatment for the Terminally Ill. Tsakopoulos A; Han J; Nodler H; Russo V Food Drug Law J; 2015; 70(4):617-41. PubMed ID: 26827394 [No Abstract] [Full Text] [Related]
50. The FDA Breakthrough-Drug Designation - Four Years of Experience. Darrow JJ; Avorn J; Kesselheim AS N Engl J Med; 2018 Apr; 378(15):1444-1453. PubMed ID: 29641970 [No Abstract] [Full Text] [Related]
51. Trouble at the office. Allison M Nat Biotechnol; 2008 Sep; 26(9):967-9. PubMed ID: 18779797 [No Abstract] [Full Text] [Related]
52. Oncology's first Phase 0 trial. Rowan K J Natl Cancer Inst; 2009 Jul; 101(14):978-9. PubMed ID: 19584322 [No Abstract] [Full Text] [Related]
53. Health roundup. Kennedy D Science; 2006 May; 312(5777):1105. PubMed ID: 16728598 [No Abstract] [Full Text] [Related]
54. DdI approval offers second chance. Albert SG Am Pharm; 1991 Dec; NS31(12):6. PubMed ID: 1763779 [No Abstract] [Full Text] [Related]
55. Pediatric drug development in anesthesiology: an FDA perspective. Schultheis LW; Mathis LL; Roca RA; Simone AF; Hertz SH; Rappaport BA Anesth Analg; 2006 Jul; 103(1):49-51. PubMed ID: 16790624 [No Abstract] [Full Text] [Related]
56. To market, to market. The nuts and bolts of prescription drug approval. Peterson AM Adv Nurse Pract; 2001 Apr; 9(4):87-90. PubMed ID: 12420443 [No Abstract] [Full Text] [Related]
57. Expanded Access to Investigational Drugs: What Physicians and the Public Need to Know about FDA and Corporate Processes. Finkelstein PE AMA J Ethics; 2015 Dec; 17(12):1142-6. PubMed ID: 26698587 [No Abstract] [Full Text] [Related]
58. Compassionate use in research. Miracle VA Dimens Crit Care Nurs; 2009; 28(2):85-8. PubMed ID: 19225323 [TBL] [Abstract][Full Text] [Related]
59. Clinical investigation of new animal drugs by veterinary practitioners. Prater DA; Bertone JJ; Letonja T; Vaughn SD J Am Vet Med Assoc; 1996 Jan; 208(2):190-4. PubMed ID: 8567369 [No Abstract] [Full Text] [Related]